The Autokit CH50 assay test kit is for the quantitative determination of total complement activity (CH50) in human serum.
The complement cascade, which consists of approximately 20 serum proteins, plays an important role in the body’s immunological defense system. Complement activity in human sera can provide important information in the diagnosis of diseases such as lupus erythematous, rheumatoid arthritis, cryoglobulinemia-vasculitis, nephritis and inherited deficiencies of the complement system. The homogenous assay for total complement activity is based on immune lysis of lyposomes.
In the assay, a sample is mixed with the lyposome and the substrate. The antibodies in the reagent combine with dinitrophenyl (DNP) on the liposomes, and then complements in the sample are activated by the antigen-antibody complex.
Activated complements break the liposome membrane. The enzyme, glucose-6-phosphate dehydrogenase (G6PDH) in the liposome reacts with nicotinamide adenine dincleotide (NAD) and glucose-6-phosphate (G6P) in the reagent. During the reaction, NAD is reduced to NAD + hydrogenase, resulting in an increased absorbance at 340nm.
Total precision studies give a 3.2 percent CV and 5.7 percent CV at mean concentrations of 48.3 and 26.9 U/mL, respectively. Assay linearity is up to 65 U/mL, and its lower detection limit is 10 U/mL.
Keyword: assay, CH50